Positron emission tomography (PET) imaging with the glucose analog 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F] FDG) has demonstrated clinical utility for the monitoring of brain glucose metabolism alteration in progressive neurodegenerative diseases. We examined dynamic [(18)F]FDG PET imaging and kinetic modeling of atlas-based regions to evaluate regional changes in the cerebral metabolic rate of glucose in the widely-used 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. Following a bolus injection of 18.5 ± 1 MBq [(18)F]FDG and a 60-minute PET scan, image-derived input functions from the vena cava and left ventricle were used with three models, including Patlak graphical analysis, to estimate the influx constant and the metabolic rate in ten brain regions. We observed statistically significant changes in [(18)F]FDG uptake ipsilateral to the 6-OHDA injection in the basal ganglia, olfactory bulb, and amygdala regions; and these changes are of biological relevance to the disease. These experiments provide further validation for the use of [(18)F]FDG PET imaging in this model for drug discovery and development.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601473 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Autophagy regulator ATG5 preserves cerebellar function by safeguarding its glycolytic activity.
Nat Metab
January 2025
CECAD Excellence Center, University of Cologne, Cologne, Germany.
Dysfunctions in autophagy, a cellular mechanism for breaking down components within lysosomes, often lead to neurodegeneration. The specific mechanisms underlying neuronal vulnerability due to autophagy dysfunction remain elusive. Here we show that autophagy contributes to cerebellar Purkinje cell (PC) survival by safeguarding their glycolytic activity.
View Article and Find Full Text PDFImpact of Ga-FAPI positron emission tomography/computed tomography on staging and tumor management in patients with gastric cancer.
J Cancer Res Clin Oncol
January 2025
Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu, Sichuan, 610041, China.
Purpose: To evaluate the added value of additional Ga-FAPI PET/CT following CT for primary staging, detection of postoperative recurrence, and management of gastric cancer patients.
Methods: We retrospectively included patients with gastric cancers who underwent contrast-enhanced computed tomography (ceCT), followed by Ga-FAPI PET/CT within 30 days. Ga-FAPI PET/CT was performed for initial staging or detection of postoperative recurrence.
Girentuximab imaging in renal cancer: diamond in the rough or just ZIRCON?
Expert Rev Anticancer Ther
January 2025
Department of Biomedical Science, Humanitas University, Pieve Emanuele, Milan, Italy.
Small renal masses (SRM), especially those under 7 cm pose significant diagnostic challenges when using conventional imaging (CT/MRI). PET/CT with [Zr]Zr-girentuximab offers a promising alternative in this setting by enabling molecular-level imaging. The ZIRCON trial, a phase 3 multicenter study, evaluated the diagnostic accuracy of [Zr]Zr-girentuximab PET/CT in detecting clear cell renal cell carcinoma (ccRCC) in SRM.
View Article and Find Full Text PDF[F]FDG PET/CT in Metastatic Extragonadal Choriocarcinoma.
J Nucl Med Technol
January 2025
Department of Medical Oncology and Haematology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Extragonadal choriocarcinoma in men is an extremely rare and highly aggressive malignancy. Inconclusive biopsies due to a high necrotic component often delay diagnosis. Here is such a case, in which suggestive imaging findings on [F]FDG PET/CT, a raised level of serum β-human chorionic gonadotropin, and gynecomastia clinched the diagnosis.
View Article and Find Full Text PDFEffectiveness of Data-Driven Gating FDG PET/CT for Abdominal Region.
J Nucl Med Technol
January 2025
Department of Nuclear Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
This study aimed to validate the effectiveness of MotionFree (MF) in the abdominal region using 2 different PET/CT scanners to determine how to use MF efficiently. All 198 patients underwent respiratory-gated F-FDG PET/CT with MF. Imaging was performed using Discovery MI (DMI) and Discovery IQ (DIQ) PET/CT scanners, and all data were divided into 2 groups in each category (abdominal: upper and lower abdomen, lesion size, <20 mm and ≥20 mm; scanner group: DMI and DIQ).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!